Business Wire

Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will host a virtual ...
Yahoo Finance

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

LOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage ...
Yahoo Finance

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. LOS ANGELES, CA, June 03, 2025 (GLOBE NEWSWIRE) ...
KSDK

VERIFY: 'Event 201' pandemic exercise didn’t predict COVID-19

Multiple claims on social media say world leaders met for a pandemic simulation right before the first new coronavirus cases were reported. Is this a coincidence or something more? Back in October, a ...
Nasdaq

Immix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025

Immix Biopharma announced significant results from its NEXICART-2 Phase 1/2 clinical trial of NXC-201 at the ASCO 2025 conference, achieving a complete response (CR) rate of 70% in patients with ...
Mena FN

Immix Biopharma Announces Primary Endpoint Met In Positive NXC-201 Interim Results Presented At ASCO, Enabling Path To Best-In-Class Therapy For Relapsed/Refractory AL Amyloidosis

(MENAFN- GlobeNewsWire - Nasdaq) Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. – NXC-201 met ...